Last 160.50 TWD
Change Today -5.07 / -3.06%
Volume 1.8M
4147 On Other Exchanges
Symbol
Exchange
Taiwan
As of 2:59 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

taimed biologics inc (4147) Snapshot

Open
164.00
Previous Close
165.57
Day High
164.00
Day Low
159.00
52 Week High
05/28/14 - 198.00
52 Week Low
01/14/14 - 63.70
Market Cap
34.7B
Average Volume 10 Days
1.9M
EPS TTM
--
Shares Outstanding
216.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TAIMED BIOLOGICS INC (4147)

Related News

No related news articles were found.

taimed biologics inc (4147) Related Businessweek News

No Related Businessweek News Found

taimed biologics inc (4147) Details

TaiMed Biologics, Inc., a biotechnology company, engages in the discovery, development, and delivery of medicines primarily for HIV/AIDS in Taiwan. Its product pipeline includes TMB-355, a phase IIb viral-entry inhibitor that blocks monoclonal antibody for the treatment of HIV/AIDS; TMB-607, a novel HIV-1 protease inhibitor; and TMB-571, a small molecule inhibitor of influenza virus neuraminidase. The company also engages in a cooperative program for 2nd generation TMB-355, and HIV integrase inhibitor program. TaiMed Biologics, Inc. was founded in 2007 and is based in Taipei, Taiwan.

Founded in 2007

taimed biologics inc (4147) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

taimed biologics inc (4147) Key Developments

WuXi PharmaTech and TaiMed Biologics Announces FDA Approve the First Batch of the ibalizumab (TMB-355) Drug

WuXi PharmaTech and TaiMed Biologics announced that the FDA has approved the first batch of the ibalizumab (TMB-355) drug substance and sterile drug product manufactured at WuXi's biologics facilities for ongoing treatment of patients under investigator-sponsored IND's. This is the first reported FDA approval of a sterile biologics product manufactured in China for use under a U.S. IND, which marks an important milestone of WuXi's investment to expedite global development of innovative biologics. Ibalizumab is a humanized monoclonal antibody and a member of an emerging class of HIV therapies known as viral-entry inhibitors. It is being developed by TaiMed Biologics for the treatment of HIV/AIDS infection. The drug substance of ibalizumab was manufactured at WuXi's cell culture manufacturing facility, which recently received an honorable mention facility-of-the-year award by ISPE. The ibalizumab drug product batch approved by the FDA was manufactured at the newly completed cGMP parenteral manufacturing facility located within the same campus as the cell culture facility at Wuxi city. The automated filling line can accommodate 2-50mL liquid and lyophilized vial products for global clinical trials and product launch.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4147:TT 160.50 TWD -5.07

4147 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4147.
View Industry Companies
 

Industry Analysis

4147

Industry Average

Valuation 4147 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 48.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAIMED BIOLOGICS INC, please visit www.taimedbiologics.com.tw. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.